University of Pennsylvania-linked CNS disorder-focused drug developer Passage Bio has filed to raise up to $125m having raised $226m in funding.

The cancer therapy developer is set to raise between $140m and $160m in its initial public offering, following $226m in funding.

The UBC bioprinting spinout will use part of the funding to progress two of its projects towards commercialisation.

Utah-founded metagenomic evaluation platform developer IDbyDNA has now raised at least $29m, with the latest round to support continued commercialisation.

The Sanofi-backed cancer therapy developer is set to raise between $140m and $160m in its initial public offering following $226m in funding.

The CNS disorder-focused drug developer has filed to raise up to $125m having raised $226m in funding from backers including Eli Lilly and Access Industries.

The financial services provider aims to secure some 200 limited partners for a vehicle that will meld industry 4.0 technology with Japan's Society 5.0 initiative.

University of Washington’s François Baneyx has sealed the job of vice-provost for innovation having administered the same duties as caretaker since February last year.

Verily has taken part in an oversubscribed series B round that will fund the UC Berkeley spinout's expansion from diagnostics to gene editing and drug development.

The online pharmacy is set to announce a series D round that will be led by $250m from SoftBank Vision Fund at a valuation in excess of $1bn.